Development and Validation of an RP-HPLC Method for the Determination of Tiazotic Acid and Its Impurity with Application to Tablet Analysis

  • Branka Ivković University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Belgrade, Serbia
  • Nemanja Turković University of Montenegro, Faculty of Medicine, Study Program Pharmacy, Montenegro, Podgorica; Institute for Medicines and Medical Devices of Montenegro, Podgorica, Montenegro
  • Milena Turković The Health Institution of the Pharmacy of Montenegro "Montefarm", Podgorica, Montenegro
  • Olivera Čudina University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Belgrade, Serbia
  • Milkica Crevar University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Belgrade, Serbia
Keywords: tiazotic acid, assay, impurity, analytical method validation, HPLC

Abstract


A simple and precise RP-HPLC method was developed and validated for the determination of tiazotic acid and its impurity, 3-methyl-1,2,4-triazole-5-thione, with application to tablet analysis. Chromatographic analysis was performed using a Hypersil GOLD aQ C18 column (150 × 4 mm, 3 µm) under isocratic elution conditions with a mobile phase consisting of phosphate buffer (pH 3.3) and methanol in a ratio of 99:1 (v/v), at a flow rate of 1 mL/min and a column temperature of 30 °C. Detection was carried out at 220 nm. The developed method was validated in accordance with ICH guidelines. The following analytical parameters were evaluated during validation: selectivity, linearity, precision, accuracy, robustness, and the limit of quantification (LOQ) for the investigated impurity. The method demonstrated linearity over the concentration range of 0.139–0.238 mg/mL (r = 0.9992) for tiazotic acid and 0.091–1.56 µg/mL (r = 0.9998) for the impurity. Good precision (RSD < 2% for tiazotic acid and RSD < 10% for the impurity), accuracy (recovery in the range of 98–102% and 70–130% for the impurity), and robustness were confirmed. The impurity 3-methyl-1,2,4-triazole-5-thione was detected in tiazotic acid tablets; however, its content was below the limit of quantification (LOQ) of the proposed method (0.091 µg/mL).

 

References

Belenichev I, Kucherenko L, Маzur I, Ryzhenko V, Khromylova O, Siusiuka V et al. Thiotriazoline and its today. Dnipro: Jurfond. 2025; 10-23.

Martindale: The Complete Drug Reference. 36th ed. Edited by Sean C. Sweetman, BPharm, FRPharmS. London: Pharmaceutical Press; 2009. Supplementary Drugs and Other Substances, p. 2400.

RU2248353C2. Method for preparing 3‑methyl‑1,2,4‑triazolyl‑5‑thioacetate morpholinium [Internet]. Russian Federation Patent; 2005. [cited 2026 Feb 12]. Available from: https://patents.google.com/patent/RU2248353C2/en#patentCitations.

Ukrainian patent No. 1988, C07D 413/12. Morpholinium 3-methyl-1,2,4-triazolyl-5-thioacetate (thiotriazoline) [Internet]. Ukraine Patent; 1988. [cited 2026 Feb 12]. Available from: https://ukrpatent.org/en/search/main.

Belenichev I, Vizir V, Mamchur V, Kuriata O. Place of Thiotriazolin in the gallery of modern metabolitotropic medicines. Zaporozhye Med J. 2019;1: 118–28.

Taschuk VK, Solobiukova NA, Makarov AA. Effectiveness of thiotriazolin in complex treatment of patients with acute coronary syndrome without ST elevation. Emergency Medicine. 2016; 8(79):35-41.

Salionov VO, Smoilovska HP. The potential of 1,2,4-triazole derivatives as antioxidant agents. Current Issues in Pharmacy and Medicine: Science and Practice. 2025; 8(1):114-118.

Kryvenko VI, Kolesnyk MYu, Bielenichev IF, Pavlov SV. Thiotriazolin effectiveness in complex treatment of patients with post-COVID syndrome. Zaporozhye Med J. 2021; 23(3):402–11.

Pachuta-Stec A. Antioxidant Activity of 1,2,4-Triazole and its Derivatives: A Mini-Review. Mini Rev Med Chem. 2022; 22(7):1081-1094.

Amosova Ye N. Metabolic treatment of myocardial injury associated with ischemia. A new approach to the treatment of coronary heart disease and heart failure. Ukr. Cardiol. Journal. 2000; 4:86-92.

ICH Q2(R2) Guideline on validation of analytical procedures. EMA/CHMP/ICH/82072/2006. Committee for Medicinal Products for Human Use [Internet]. EMA; 2023. [cited 2026 Feb 13]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf.

Published
2026/04/29
Section
Original scientific paper